KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) EBITDA Margin (2016 - 2025)

Alnylam Pharmaceuticals' EBITDA Margin history spans 16 years, with the latest figure at 10.32% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 2608.0% year-over-year to 10.32%; the TTM value through Dec 2025 reached 9.29%, up 2215.0%, while the annual FY2025 figure was 8.84%, 2170.0% up from the prior year.
  • EBITDA Margin reached 10.32% in Q4 2025 per ALNY's latest filing, down from 20.76% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 20.76% in Q3 2025 to a low of 154.17% in Q3 2022.
  • Average EBITDA Margin over 5 years is 55.38%, with a median of 57.49% recorded in 2022.
  • Peak YoY movement for EBITDA Margin: surged 17449bps in 2023, then tumbled -5676bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 99.6% in 2021, then surged by 38bps to 62.19% in 2022, then surged by 53bps to 29.32% in 2023, then soared by 46bps to 15.76% in 2024, then skyrocketed by 166bps to 10.32% in 2025.
  • Per Business Quant, the three most recent readings for ALNY's EBITDA Margin are 10.32% (Q4 2025), 20.76% (Q3 2025), and 7.59% (Q2 2025).